The concerned officials of Ranbaxy stated that the company acquired trademarks, product dossiers and marketing rights from the Ochoa Laboratories Ltd for its entire range of dermatological and lifestyle products.

Ranbaxy, which has already gained a notable position in the dermatology market, has launched steroids with products like Zole-F, Suncros, Efflora, Fucidin and Teczine.

But the company officials have not disclosed any financial details.

Ochoa Laboratories Ltd has sound command and commendable equity with medical professionals. The respective products of this company are also considered as market leaders in its respective categories. Even the Ochoa also praised Ranbaxy's existing derma portfolio.

The current market size of Ranbaxy’s dermatology segments in India is around INR 1,950 crore. The company’s market is increasing rapidly at around 11 per cent every year. The products of Ranbaxy usually enjoy high margins because of its brand appeal.

Ranbaxy Laboratories Limited is the largest pharmaceutical company of India. Established in 1961, Ranbaxy exports its various pharmaceutical products to 125 countries. It has ground operations in 46 countries and also has manufacturing facilities in seven countries. The CEO of the company is Malvinder Mohan Singh.